Teaching resource, lantus Molly Weaver

Teaching resource, lantus Molly Weaver

Published on 25 April 2022
  • Facebook
  • Twitter
  • Linkedin
Transcript
00:01
Long acting insulin: Lantus insulin glargine [rDNA origin] injection
00:02
MollyWeaver
00:05
small amounts of insulin glargine are slowly released, resulting in a relatively constant concentration time profile over 24 hours with no peak  this makes it a patient’s basal insulin comes in subq injection or orally.
00:06
Pharmacodynamics
00:07
00:08
00:10
After subcutaneous injection of insulin glargine in healthy subjects and in patients with diabetes, the insulin serum concentrations indicated a slower, more prolonged absorption and a relatively constant concentration/time profile over 24 hours
00:10
Pharmacokinetics
00:15
00:15
Uses
00:17
00:17
improve glycemic control in patients with type 1 diabetes mellitus
00:17
Improve glycemic control in patients with type 2 diabetes mellitus 
00:23
Special Implications
00:24
Contraindicated during episodes of hypoglycemia or diabetic ketoacidosis. drug interactions with ACE inhibitors, Beta-blockers Discourage drinking alcohol
00:28
Possible adverse reactions 
00:28
allergic reactions to the diluent site injection reactions or infection lipodystrophy at the injection site Hypoglycemia know what signs and symptoms 
00:28
help keep blood sugar within normal ranges
00:28
Therapeutic effects expected
00:34
Question 1) what is lantus used to treat?
00:34
Question2) True or False, patient should continue to drink alcohol?